Drug choices in the treatment of atrial fibrillation
- 1 May 2000
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 85 (10) , 12-19
- https://doi.org/10.1016/s0002-9149(00)00902-4
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Atrial fibrillation: nonpharmacologic approachesThe American Journal of Cardiology, 2000
- Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapyThe American Journal of Cardiology, 2000
- Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decisionThe American Journal of Cardiology, 1998
- Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillationHeart, 1998
- Rhythm Management in Atrial Fibrillation—With a Primary Emphasis on Pharmacologic Therapy: Part 3Pacing and Clinical Electrophysiology, 1998
- Rhythm Management in Atrial Fibrillation—with a Primary Emphasis on Pharmacological Therapy: Part 2Pacing and Clinical Electrophysiology, 1998
- Rhythm Management in Atrial Fibrillation—With a Primary Emphasis on Pharmacological Therapy: Part 1Pacing and Clinical Electrophysiology, 1998
- Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or FibrillationCirculation, 1996
- Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response studyJournal of the American College of Cardiology, 1996
- Management of Patients With Atrial FibrillationCirculation, 1996